The Merck collaboration will concentrate on using the device alongside anti-inflammatory ... The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the ...
A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...
Here are 10 of the best health care stocks to buy in 2024, according to CFRA analysts: *As of Sept. 10 close. Based on ...
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
Meniscus Tear Clinical Trial Progression: The market is poised for substantial growth, fueled by the anticipated launch of ...
The FDA issued draft guidance on oncology clinical trials, taking the first steps toward formalizing a position that it's ...
heartbeat and other biomarkers that are essential for assessing health and medical conditions." Merck's interest in Hyfe is another example of big pharma's move into the digital health arena with ...
Merck and Siemens have signed a strategic partnership to accelerate digital transformation in manufacturing through smart, ...
According to recently unveiled statistics by Future Market Insights, the global animal artificial insemination market is set ...
The flexible electronic market is estimated to be valued at USD 37,065.0 million in 2023. Projections suggest that the ...
Merck’s Keytruda plus Padcev receives European approval for first-line treatment of unresectable or metastatic urothelial carcinoma in adults: Rahway, New Jersey Wednesday, Sept ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback